BUSINESS
Kyowa Kirin Says It’s Steadily Pursuing Nesp Authorized Biosimilar Program, but Silent on Details
Kyowa Hakko Kirin is steadily pursuing its Nesp (darbepoetin alfa) authorized biosimilar (AB) program towards its approval, company executives said at earnings conference on July 31, but they disclosed none of its details, including its development and filing status. “At…
To read the full story
Related Article
- Kyowa Kirin Sets Up New Firm for Nesp Authorized Biosimilar
February 1, 2017
BUSINESS
- Terumo to Take US$610 Million Hit as CSL Plasma Supply Deal Ends
October 9, 2026
- Ono Gets Japan, Asia Rights to 3 IgG Degraders from Biohaven
October 9, 2026
- Datroway Snares TNBC Approval in China: Daiichi Sankyo
October 9, 2026
- Enhertu Gains Adjuvant Nod in China for HER2-Positive Breast Cancer
October 9, 2026
- Parexel Revs Up AI Drive, Targets 6-Month Trial Time Cut
October 8, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





